# A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies

> **NCT01476657** · PHASE1 · TERMINATED · sponsor: **SecuraBio** · enrollment: 210 (actual)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** IPI-145 (duvelisib)

## Key facts

- **NCT ID:** NCT01476657
- **Lead sponsor:** SecuraBio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10
- **Primary completion:** 2016-12
- **Final completion:** 2017-01
- **Target enrollment:** 210 (ACTUAL)
- **Why stopped:** The scope of the program has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.
- **Last updated:** 2021-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01476657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01476657, "A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01476657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*